Krensavage Asset Management LLC Reduces Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Krensavage Asset Management LLC trimmed its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 75.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 100,332 shares of the biopharmaceutical company's stock after selling 314,352 shares during the period. Vanda Pharmaceuticals comprises approximately 0.3% of Krensavage Asset Management LLC's portfolio, making the stock its 10th largest position. Krensavage Asset Management LLC owned about 0.17% of Vanda Pharmaceuticals worth $481,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its stake in shares of Vanda Pharmaceuticals by 16.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 160,722 shares of the biopharmaceutical company's stock valued at $754,000 after acquiring an additional 22,249 shares during the last quarter. SG Americas Securities LLC lifted its position in Vanda Pharmaceuticals by 26.8% in the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock valued at $124,000 after purchasing an additional 5,459 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Vanda Pharmaceuticals by 4.9% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company's stock valued at $3,925,000 after purchasing an additional 38,449 shares during the period. Monaco Asset Management SAM grew its holdings in shares of Vanda Pharmaceuticals by 92.8% in the fourth quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company's stock worth $1,879,000 after purchasing an additional 188,836 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Vanda Pharmaceuticals by 2.1% in the fourth quarter. American Century Companies Inc. now owns 300,276 shares of the biopharmaceutical company's stock worth $1,438,000 after purchasing an additional 6,079 shares during the last quarter. 88.14% of the stock is owned by institutional investors.

Insider Buying and Selling at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos bought 20,000 shares of the company's stock in a transaction dated Friday, May 16th. The shares were purchased at an average price of $4.22 per share, for a total transaction of $84,400.00. Following the acquisition, the chief executive officer now owns 2,315,731 shares in the company, valued at approximately $9,772,384.82. This represents a 0.87% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In the last three months, insiders have bought 60,000 shares of company stock valued at $270,800. 8.90% of the stock is currently owned by corporate insiders.

Vanda Pharmaceuticals Stock Performance

Shares of Vanda Pharmaceuticals stock traded up $0.09 during midday trading on Friday, reaching $4.33. 296,763 shares of the company's stock traded hands, compared to its average volume of 717,189. The stock has a 50 day moving average of $4.36 and a 200-day moving average of $4.62. Vanda Pharmaceuticals Inc. has a 12 month low of $3.81 and a 12 month high of $6.75. The company has a market cap of $255.18 million, a PE ratio of -13.53 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The business had revenue of $50.04 million for the quarter, compared to the consensus estimate of $45.13 million. On average, equities analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on VNDA shares. Cantor Fitzgerald reissued an "overweight" rating and set a $13.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th. HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a report on Wednesday, May 7th. Finally, Wall Street Zen assumed coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a "hold" rating on the stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.